CRVO Stock Summary and Trading Ideas (Cervomed | NASDAQ:CRVO)

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Cervomed trades on the NASDAQ stock market under the symbol CRVO.

As of September 29, 2026, CRVO stock price climbed to $2.88 with 414,687 million shares trading.

CRVO has a beta of 2.04, meaning it tends to be more sensitive to market movements. CRVO has a correlation of 0.09 to the broad based SPY ETF.

CRVO has a market cap of $43.54 million. This is considered a Sub-Micro Cap stock.

Last quarter Cervomed reported $0 in Revenue and -$.64 earnings per share. This fell short of revenue expectation by $-140,000 and exceeded earnings estimates by $.23.

In the last 3 years, CRVO traded as high as $26.38 and as low as $1.80.

The top ETF exchange traded funds that CRVO belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

CRVO has underperformed the market in the last year with a return of -65.2%, while the SPY ETF gained +16.6%. In the last 3 month period, CRVO fell short of the market, returning -17.5%, while SPY returned +5.1%. However, in the most recent 2 weeks CRVO has outperformed the stock market by returning +13.8%, while SPY returned +0.7%.

CRVO support price is $2.58 and resistance is $2.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVO shares will trade within this expected range on the day.